93 related articles for article (PubMed ID: 30731403)
1. A missense variant in PTPN12 associated with the risk of colorectal cancer by modifying Ras/MEK/ERK signaling.
Shen N; Li L; Xu W; Tian J; Yang Y; Zhu Y; Gong Y; Ke J; Gong J; Chang J; Zhong R; Miao X
Cancer Epidemiol; 2019 Apr; 59():109-114. PubMed ID: 30731403
[TBL] [Abstract][Full Text] [Related]
2. Identification of Novel Candidate Genes for Early-Onset Colorectal Cancer Susceptibility.
de Voer RM; Hahn MM; Weren RD; Mensenkamp AR; Gilissen C; van Zelst-Stams WA; Spruijt L; Kets CM; Zhang J; Venselaar H; Vreede L; Schubert N; Tychon M; Derks R; Schackert HK; Geurts van Kessel A; Hoogerbrugge N; Ligtenberg MJ; Kuiper RP
PLoS Genet; 2016 Feb; 12(2):e1005880. PubMed ID: 26901136
[TBL] [Abstract][Full Text] [Related]
3. A low-frequency variant in SMAD7 modulates TGF-β signaling and confers risk for colorectal cancer in Chinese population.
Li J; Zou L; Zhou Y; Li L; Zhu Y; Yang Y; Gong Y; Lou J; Ke J; Zhang Y; Tian J; Zou D; Peng X; Chang J; Gong J; Zhong R; Zhou X; Miao X
Mol Carcinog; 2017 Jul; 56(7):1798-1807. PubMed ID: 28218435
[TBL] [Abstract][Full Text] [Related]
4. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine phosphatases in the HER2-directed motility of ovarian cancer cells: Involvement of PTPN12, ERK5 and FAK.
Villa-Moruzzi E
Anal Cell Pathol (Amst); 2011; 34(3):101-12. PubMed ID: 21483099
[TBL] [Abstract][Full Text] [Related]
6. A loss-of-function screen for phosphatases that regulate neurite outgrowth identifies PTPN12 as a negative regulator of TrkB tyrosine phosphorylation.
Ambjørn M; Dubreuil V; Miozzo F; Nigon F; Møller B; Issazadeh-Navikas S; Berg J; Lees M; Sap J
PLoS One; 2013; 8(6):e65371. PubMed ID: 23785422
[TBL] [Abstract][Full Text] [Related]
7. Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma.
Xu Y; Taylor P; Andrade J; Ueberheide B; Shuch B; Glazer PM; Bindra RS; Moran MF; Linehan WM; Neel BG
Cancer Res; 2018 Dec; 78(23):6539-6548. PubMed ID: 30297534
[TBL] [Abstract][Full Text] [Related]
8. Switching of the substrate specificity of protein tyrosine phosphatase N12 by cyclin-dependent kinase 2 phosphorylation orchestrating 2 oncogenic pathways.
Li H; Yang D; Ning S; Xu Y; Yang F; Yin R; Feng T; Han S; Guo L; Zhang P; Qu W; Guo R; Song C; Xiao P; Zhou C; Xu Z; Sun JP; Yu X
FASEB J; 2018 Jan; 32(1):73-82. PubMed ID: 28842430
[TBL] [Abstract][Full Text] [Related]
9. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase.
Sun T; Aceto N; Meerbrey KL; Kessler JD; Zhou C; Migliaccio I; Nguyen DX; Pavlova NN; Botero M; Huang J; Bernardi RJ; Schmitt E; Hu G; Li MZ; Dephoure N; Gygi SP; Rao M; Creighton CJ; Hilsenbeck SG; Shaw CA; Muzny D; Gibbs RA; Wheeler DA; Osborne CK; Schiff R; Bentires-Alj M; Elledge SJ; Westbrook TF
Cell; 2011 Mar; 144(5):703-18. PubMed ID: 21376233
[TBL] [Abstract][Full Text] [Related]
10. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.
Nair A; Chung HC; Sun T; Tyagi S; Dobrolecki LE; Dominguez-Vidana R; Kurley SJ; Orellana M; Renwick A; Henke DM; Katsonis P; Schmitt E; Chan DW; Li H; Mao S; Petrovic I; Creighton CJ; Gutierrez C; Dubrulle J; Stossi F; Tyner JW; Lichtarge O; Lin CY; Zhang B; Scott KL; Hilsenbeck SG; Sun J; Yu X; Osborne CK; Schiff R; Christensen JG; Shields DJ; Rimawi MF; Ellis MJ; Shaw CA; Lewis MT; Westbrook TF
Nat Med; 2018 May; 24(4):505-511. PubMed ID: 29578538
[TBL] [Abstract][Full Text] [Related]
11. Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition.
Li J; Davidson D; Martins Souza C; Zhong MC; Wu N; Park M; Muller WJ; Veillette A
Mol Cell Biol; 2015 Dec; 35(23):4069-82. PubMed ID: 26391955
[TBL] [Abstract][Full Text] [Related]
12. PTPN12 promotes resistance to oxidative stress and supports tumorigenesis by regulating FOXO signaling.
Harris IS; Blaser H; Moreno J; Treloar AE; Gorrini C; Sasaki M; Mason JM; Knobbe CB; Rufini A; Hallé M; Elia AJ; Wakeham A; Tremblay ML; Melino G; Done S; Mak TW
Oncogene; 2014 Feb; 33(8):1047-54. PubMed ID: 23435421
[TBL] [Abstract][Full Text] [Related]
13. Important roles of protein tyrosine phosphatase PTPN12 in tumor progression.
Lee C; Rhee I
Pharmacol Res; 2019 Jun; 144():73-78. PubMed ID: 30959160
[TBL] [Abstract][Full Text] [Related]
14. High PTPRQ Expression and Its Relationship to Expression of PTPRZ1 and the Presence of KRAS Mutations in Colorectal Cancer Tissues.
Laczmanska I; Karpinski P; Gil J; Laczmanski L; Bebenek M; Sasiadek MM
Anticancer Res; 2016 Feb; 36(2):677-81. PubMed ID: 26851024
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma.
Cao X; Li Y; Luo RZ; He LR; Yang J; Zeng MS; Wen ZS
Ann Thorac Surg; 2012 May; 93(5):1674-80. PubMed ID: 22429674
[TBL] [Abstract][Full Text] [Related]
16. Association Between Germline Mutations in BRF1, a Subunit of the RNA Polymerase III Transcription Complex, and Hereditary Colorectal Cancer.
Bellido F; Sowada N; Mur P; Lázaro C; Pons T; Valdés-Mas R; Pineda M; Aiza G; Iglesias S; Soto JL; Urioste M; Caldés T; Balbín M; Blay P; Rueda D; Durán M; Valencia A; Moreno V; Brunet J; Blanco I; Navarro M; Calin GA; Borck G; Puente XS; Capellá G; Valle L
Gastroenterology; 2018 Jan; 154(1):181-194.e20. PubMed ID: 28912018
[TBL] [Abstract][Full Text] [Related]
17. One-carbon metabolism biomarkers and genetic variants in relation to colorectal cancer risk by KRAS and BRAF mutation status.
Myte R; Gylling B; Häggström J; Schneede J; Löfgren-Burström A; Huyghe JR; Hallmans G; Meyer K; Johansson I; Ueland PM; Palmqvist R; Van Guelpen B
PLoS One; 2018; 13(4):e0196233. PubMed ID: 29694444
[TBL] [Abstract][Full Text] [Related]
18. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
Song Q; Sun X; Guo H; Yu Q
Oncotarget; 2017 Jan; 8(3):5003-5015. PubMed ID: 28002807
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer.
Seiden-Long IM; Brown KR; Shih W; Wigle DA; Radulovich N; Jurisica I; Tsao MS
Oncogene; 2006 Jan; 25(1):91-102. PubMed ID: 16158056
[TBL] [Abstract][Full Text] [Related]
20. Genetic variants in IL-6/JAK/STAT3 pathway and the risk of CRC.
Wang S; Zhang W
Tumour Biol; 2016 May; 37(5):6561-9. PubMed ID: 26638167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
